Antibiotic treatment outcomes in community-acquired pneumonia

Creative Commons License

ÇİLLİ A., SAYINER A., ÇELENK B., Sakar Coskun A., KILINÇ O., Hazar A., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.48, sa.4, ss.730-736, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 48 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.3906/sag-1709-144
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.730-736
  • Anahtar Kelimeler: Pneumonia, beta-lactam, fluoroquinolone, macrolide, BETA-LACTAM MONOTHERAPY, ADULTS, RESISTANCE, MACROLIDES, MORTALITY, THERAPY, GUIDELINES, MANAGEMENT, PATHOGENS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with community-acquired pneumonia in nonintensive care unit (ICU) wards and treated with a beta-lactam, beta-lactam and macrolide combination, or a fluoroquinolone.